Second Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a))

Introduction: The Metabolic Syndrome is a set of diverse clinical situations such as diabetes mellitus, hypertension and dyslipidemia. Patients with mental illnesses such as schizophrenia or bipolar disorder have a higher mortality than the general population attributable in 60% to somatic diseases...

Full description

Autores:: Roldan Menco, Consuelo
Díaz-Pérez, Anderson
Barrios Puerta, Zoraida

Tipo de recurso:

Fecha de publicación:: 2019

Institución:: Universidad Simón Bolívar

Repositorio:: Repositorio Digital USB

Idioma:: eng

id	USIMONBOL2_5e2f00c40584a4d4ed61193b92f05a15
oai_identifier_str	oai:bonga.unisimon.edu.co:20.500.12442/3021
network_acronym_str	USIMONBOL2
network_name_str	Repositorio Digital USB
repository_id_str
dc.title.eng.fl_str_mv	Second Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a))
title	Second Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a))
spellingShingle	Second Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a)) Second generation antipsychotics Schizophrenic patients Bipolar disorder Metabolic syndrome
title_short	Second Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a))
title_full	Second Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a))
title_fullStr	Second Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a))
title_full_unstemmed	Second Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a))
title_sort	Second Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a))
dc.creator.fl_str_mv	Roldan Menco, Consuelo Díaz-Pérez, Anderson Barrios Puerta, Zoraida
dc.contributor.author.none.fl_str_mv	Roldan Menco, Consuelo Díaz-Pérez, Anderson Barrios Puerta, Zoraida
dc.subject.eng.fl_str_mv	Second generation antipsychotics Schizophrenic patients Bipolar disorder Metabolic syndrome
topic	Second generation antipsychotics Schizophrenic patients Bipolar disorder Metabolic syndrome
description	Introduction: The Metabolic Syndrome is a set of diverse clinical situations such as diabetes mellitus, hypertension and dyslipidemia. Patients with mental illnesses such as schizophrenia or bipolar disorder have a higher mortality than the general population attributable in 60% to somatic diseases and metabolic syndrome, where second generation antipsychotics increase the risk of weight gain and insulin resistance. Objectives. Correlate the treatment with second generation antipsychotics (SGAs) as a possible predictor for Metabolic Syndrome according to the NCEP ATP III (a) classification. Methods: Descriptive, cross-sectional correlational study. The sample was of 92 patients, applying an open and convenience sampling due to the mental state of the patients in order to determine their degree of acceptance to the study (Informed Assent) and consent to the legal guardian as the main inclusion criterion. For the analysis, the following variables were considered: blood pressure, weight, height, abdominal circumference, serum levels of triglycerides, glucose and high density lipoproteins. The SPSS 20.0 ® program was used logistic regression analysis with a p-value <0.05 and a confidence level of 95%. Results: SGAs most used was clozapine (54.3%). The correlation analysis showed that sociodemographic aspects such as personal history, habits, physical activity and paraclinical and anthropometric records correlated with the possible diagnosis of metabolic syndrome (p <0.05), but not with SGAs (p> 0.05). ). Conclusion: No correlation was found between the presence of the metabolic syndrome and the type of antipsychotic treatment.
publishDate	2019
dc.date.accessioned.none.fl_str_mv	2019-05-15T20:00:01Z
dc.date.available.none.fl_str_mv	2019-05-15T20:00:01Z
dc.date.issued.none.fl_str_mv	2019
dc.type.eng.fl_str_mv	article
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.identifier.issn.none.fl_str_mv	19169736
dc.identifier.uri.none.fl_str_mv	http://hdl.handle.net/20.500.12442/3021
identifier_str_mv	19169736
url	http://hdl.handle.net/20.500.12442/3021
dc.language.iso.eng.fl_str_mv	eng
language	eng
dc.rights.*.fl_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.uri.*.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/4.0/
rights_invalid_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2
dc.publisher.eng.fl_str_mv	Canadian Center of Science and Education
dc.source.eng.fl_str_mv	Global Journal of Health Sciencia Vol. 11, No. 1 (2019)
institution	Universidad Simón Bolívar
dc.source.uri.eng.fl_str_mv	https://doi.org/10.5539/gjhs.v11n1p28
bitstream.url.fl_str_mv	https://bonga.unisimon.edu.co/bitstreams/2d193d4a-75e8-4a16-94dc-e1e5a718944b/download https://bonga.unisimon.edu.co/bitstreams/51a6e066-14a7-4a95-9251-2e91a43e967a/download https://bonga.unisimon.edu.co/bitstreams/e7dfd892-98e5-40bb-b5f1-aea823f8385d/download https://bonga.unisimon.edu.co/bitstreams/9372a9ad-c152-41e6-8c70-1a6af10e3db4/download https://bonga.unisimon.edu.co/bitstreams/59c514b5-614e-4a60-a330-a13f43cd85a7/download https://bonga.unisimon.edu.co/bitstreams/0e503c74-b09e-48e9-8dc9-7d89f9fd07b8/download https://bonga.unisimon.edu.co/bitstreams/d74fbe2f-8825-4a7e-b08e-70144926d622/download
bitstream.checksum.fl_str_mv	fc05a0801e49f04b92c4b8668f4e887b 4460e5956bc1d1639be9ae6146a50347 3fdc7b41651299350522650338f5754d a0b7eefb49762645a24f55d316a1fb33 40d7b186e44e838fd40b9ef72f4376db 2bc2614ff9fbae06862fcfbcddd735ed 8a6e6c9ad5ebc6e57e806bfde4856b10
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Digital Universidad Simón Bolívar
repository.mail.fl_str_mv	repositorio.digital@unisimon.edu.co
_version_	1814076139883200512
spelling	Roldan Menco, Consuelo67bd2bae-c096-40a2-91ad-84a89c6b6ebcDíaz-Pérez, Anderson1c41cfcd-6b03-4ec2-a737-8299ac90ad88Barrios Puerta, Zoraida2d6bac6d-6622-4d8d-bd9a-55b8789da0cb2019-05-15T20:00:01Z2019-05-15T20:00:01Z201919169736http://hdl.handle.net/20.500.12442/3021Introduction: The Metabolic Syndrome is a set of diverse clinical situations such as diabetes mellitus, hypertension and dyslipidemia. Patients with mental illnesses such as schizophrenia or bipolar disorder have a higher mortality than the general population attributable in 60% to somatic diseases and metabolic syndrome, where second generation antipsychotics increase the risk of weight gain and insulin resistance. Objectives. Correlate the treatment with second generation antipsychotics (SGAs) as a possible predictor for Metabolic Syndrome according to the NCEP ATP III (a) classification. Methods: Descriptive, cross-sectional correlational study. The sample was of 92 patients, applying an open and convenience sampling due to the mental state of the patients in order to determine their degree of acceptance to the study (Informed Assent) and consent to the legal guardian as the main inclusion criterion. For the analysis, the following variables were considered: blood pressure, weight, height, abdominal circumference, serum levels of triglycerides, glucose and high density lipoproteins. The SPSS 20.0 ® program was used logistic regression analysis with a p-value <0.05 and a confidence level of 95%. Results: SGAs most used was clozapine (54.3%). The correlation analysis showed that sociodemographic aspects such as personal history, habits, physical activity and paraclinical and anthropometric records correlated with the possible diagnosis of metabolic syndrome (p <0.05), but not with SGAs (p> 0.05). ). Conclusion: No correlation was found between the presence of the metabolic syndrome and the type of antipsychotic treatment.engCanadian Center of Science and EducationAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/http://purl.org/coar/access_right/c_abf2Global Journal of Health ScienciaVol. 11, No. 1 (2019)https://doi.org/10.5539/gjhs.v11n1p28Second generation antipsychoticsSchizophrenic patientsBipolar disorderMetabolic syndromeSecond Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a))articlehttp://purl.org/coar/resource_type/c_6501Aguilar, E., Coronas, R., & Caixàs, A. (2012). Síndrome metabólico en pacientes esquizofrénicos con tratamiento antipsicótico. Medicina clínica, 139(12), 542-546. https://doi.org/10.1016/j.medcli.2012.05.028Correll, C. U., Detraux, J., Lepeleire, J., & De Hert, M. (2015). Efectos de antipsicóticos, antidepresivos y estabilizadores del estado de ánimo sobre el riesgo de enfermedades físicas en personas con esquizofrenia, depresión y trastorno bipolar. WPA, 14, 119-136.Cortés Morales, B. (2011). Síndrome metabólico y antipsicóticos de segunda generación. Revista de la Asociación Espa-ola de Neuropsiquiatría, 31(2), 303-320. https://doi.org/10.4321/S0211-57352011000200009De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., & Möller, H.-J. (2009). Enfermedad cardiovascular y diabetes en personas con enfermedad mental grave: Declaración de la posición de la Sociedad Psiquiátrica Europea (EPA), respaldada por la Asociación Europea para el Estudio de la Diabetes (EASD) y la Sociedad Europea de Cardiología (ESC). Revista de Psiquiatría y Salud Mental, 2(1), 49-59. https://doi.org/10.1016/S1888-9891(09)70714-1Estévez, M. J. V., Domínguez, M. F., Corti-as, M. J. L., Seoane, M. N., Sánchez, E. P., & Quintas, C. M. G. (2013). Prevalencia del síndrome metabólico en esquizofrenia y trastorno bipolar:?` sería útil un protocolo de control cardiovascular? Cadernos de atención primaria, 19(4), 215–222.García-García, E., la Llata-Romero, D., Kaufer-Horwitz, M., Tusié-Luna, M. T., Calzada-León, R., Vázquez-Velázquez, V., … Velázquez-Fernández, D. (2008). La obesidad y el síndrome metabólico como problema de salud pública. Una reflexión. Acta pediátrica de México, 29(4), 227-245.Jaramillo, C. L., Mejía, A. C., Velásquez, A. H., Palacio, T. F. R., & Zuluaga, J. O. (2013). Síndrome metabólico y trastorno afectivo bipolar: una revisión de la literatura. Revista Colombiana de Psiquiatría, 42(3), 283-291. https://doi.org/10.1016/S0034-7450(13)70021-0Levav, I., Lima, B. R., Somoza Lennon, M., Kramer, M., & Salvatierra-González, R. (1989). Salud mental para todos en America Latina y el Caribe: bases epidemiologicas para la accion.Martinez, M. I. V., León, F., Torres, R., & Crossley, N. A. (2017). Antipsicóticos de primera y segunda generación en esquizofrenia: eficacia, efectividad y efecto de la dosis utilizada. ARS MEDICA Revista de Ciencias Médicas, 42(1), 41-48. https://doi.org/10.11565/arsmed.v42i1.452Menco, C. R., & Pérez, A. D. (2011). Otros factores asociados con síndrome metabólico? Ciencia y Salud Virtual, 3(1), 135-143. https://doi.org/10.22519/21455333.300Moreno, T. S.-A., González, R. T., Fleta, J. L. H., & Pérez, P. L. (2006). Alta prevalencia de síndrome metabólico en pacientes esquizofrénicos: una revisión de la literatura. Psiquiatría Biológica, 13(4), 127–135. https://doi.org/10.1016/S1134-5934(06)75353-2Mu-oz, P., & Gallardo, R. (2004). Trastornos metabólicos en pacientes esquizofrénicos tratados con Clozapina.Mu-oz-Calero Franco, P., Sánchez Sánchez, B., Rodríguez Criado, N., Pinilla Santos, B., Bravo Herrero, S., Fourcade, C., … Martín Aragón, R. (2015). Síndrome metabólico y riesgo cardiovascular en pacientes con diagnóstico de esquizofrenia, trastorno esquizoafectivo y trastorno bipolar. Nutrición Hospitalaria, 32(6), 2715–2717.Ortiz Lobo, A., & Ibá-ez Rojo, V. (2011). Iatrogenia y prevención cuaternaria en salud mental. Revista Espa-ola de Salud Pública, 85(6), 513-525. https://doi.org/10.1590/S1135-57272011000600002Pato, C. M. F., Rodríguez, V. M., & Valverde, J. I. F. (2017). Síndrome metabólico y antipsicóticos atípicos. Posibilidad de predicción y control. Revista de Psiquiatría y Salud Mental, 10(1), 38-44. https://doi.org/10.1016/j.rpsm.2016.09.003Pineda, C. A. (2008). Síndrome metabólico: definición, historia, criterios. Colombia médica, 39(1).Rojo, L., Mesa, F., & Martínez-Ortega, J. M. (2014). Prevalencia del síndrome metabólico en pacientes espa-oles con esquizofrenia y sobrepeso. El estudio CRESSOB. Actas Esp Psiquiatr, 42(1), 9-17.Alberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006). Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabetic medicine, 23(5), 469-480. https://doi.org/10.1111/j.1464-5491.2006.01858.xAtun, R., De Andrade, L. O. M., Almeida, G., Cotlear, D., Dmytraczenko, T., Frenz, P., … Muntaner, C. (2015). Health-system reform and universal health coverage in Latin America. The Lancet, 385(9974), 1230-1247. https://doi.org/10.1016/S0140-6736(14)61646-9Choo CC, Chew PKH, Ho CS, Ho RC. Prediction of Quality of Life in Asian Patients with Schizophrenia: A Cross-sectional Pilot Study. Front Psychiatry, 5(8), 198. https://doi.org/10.3389/fpsyt.2017.00198Expert Panel on Detection, E. (2001). Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Jama, 285(19), 2486. https://doi.org/10.1001/jama.285.19.2486Firmann, M., Mayor, V., Vidal, P. M., Bochud, M., Pécoud, A., Hayoz, D., … Yuan, X. (2008). The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC cardiovascular disorders, 8(1), 6. https://doi.org/10.1186/1471-2261-8-6Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., … Program, C. C. of the N. C. E. (2004). Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Journal of the American College of Cardiology, 44(3), 720-732. https://doi.org/10.1016/j.jacc.2004.07.001Heng, D., Ma, S., Lee, J. J., Tai, B. C., Mak, K. H., Hughes, K., … Tai, E. S. (2006). Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis, 186(2), 367-373. https://doi.org/10.1016/j.atherosclerosis.2005.07.020Ho, C. S., Zhang, M. W., Mak, A., Ho, R. C. (2014). Metabolic syndrome in psychiatry: advances in understanding and management. Advances in Psychiatric Treatment, 20, 101-112. https://doi.org/10.1192/apt.bp.113.011619Kavey, R.-E. W., Daniels, S. R., Lauer, R. M., Atkins, D. L., Hayman, L. L., & Taubert, K. (2003). American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation, 107(11), 1562–1566. https://doi.org/10.1161/01.CIR.0000061521.15730.6ELakka, H.-M., Laaksonen, D. E., Lakka, T. A., Niskanen, L. K., Kumpusalo, E., Tuomilehto, J., & Salonen, J. T. (2002). The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Jama, 288(21), 2709-2716. https://doi.org/10.1001/jama.288.21.2709McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., … Lieberman, J. A. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia research, 80(1), 19-32. https://doi.org/10.1016/j.schres.2005.07.014Newcomer, J. W. (2007a). Antipsychotic medications: metabolic and cardiovascular risk. The Journal of clinical psychiatry.Newcomer, J. W. (2007b). Metabolic syndrome and mental illness. The American journal of managed care, 13(7 Suppl), S170-7.Park, B., & Lee, Y.-J. (2018). Metabolic syndrome and its components as risk factors for prolonged corrected QT interval in apparently healthy Korean men and women. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2018.07.004Stergiou, G. S., Asmar, R., Myers, M., Palatini, P., Parati, G., Shennan, A., … Monitoring, E. S. of H. W. G. on B. P. (2018). Improving the accuracy of blood pressure measurement: the influence of the European Society of Hypertension International Protocol (ESH-IP) for the validation of blood pressure measuring devices and future perspectives. LWW. https://doi.org/10.1097/HJH.0000000000001635Thomas, G. N., Ho, S.-Y., Janus, E. D., Lam, K. S., Hedley, A. J., Lam, T. H., & Committee, H. K. C. R. F. P. S. S. (2005). The US national cholesterol education programme adult treatment panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population. Diabetes research and clinical practice, 67(3), 251-257. https://doi.org/10.1016/j.diabres.2004.07.022Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., … Correll, C. U. (2015). Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry, 14(3), 339-347. https://doi.org/10.1002/wps.20252Williams, B., Poulter, N. R., Brown, M. J., Davis, M., McInnes, G. T., Potter, J. F., … Thom, S. M. (2004). Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. Journal of human hypertension, 18(3), 139. https://doi.org/10.1038/sj.jhh.1001683ORIGINALPDF.pdfPDF.pdfPDFapplication/pdf200739https://bonga.unisimon.edu.co/bitstreams/2d193d4a-75e8-4a16-94dc-e1e5a718944b/downloadfc05a0801e49f04b92c4b8668f4e887bMD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://bonga.unisimon.edu.co/bitstreams/51a6e066-14a7-4a95-9251-2e91a43e967a/download4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8368https://bonga.unisimon.edu.co/bitstreams/e7dfd892-98e5-40bb-b5f1-aea823f8385d/download3fdc7b41651299350522650338f5754dMD53TEXTSecond Generation Antipsychotics (SGAs) in Schizophrenic Patients .pdf.txtSecond Generation Antipsychotics (SGAs) in Schizophrenic Patients .pdf.txtExtracted texttext/plain31458https://bonga.unisimon.edu.co/bitstreams/9372a9ad-c152-41e6-8c70-1a6af10e3db4/downloada0b7eefb49762645a24f55d316a1fb33MD54PDF.pdf.txtPDF.pdf.txtExtracted texttext/plain31657https://bonga.unisimon.edu.co/bitstreams/59c514b5-614e-4a60-a330-a13f43cd85a7/download40d7b186e44e838fd40b9ef72f4376dbMD56THUMBNAILSecond Generation Antipsychotics (SGAs) in Schizophrenic Patients .pdf.jpgSecond Generation Antipsychotics (SGAs) in Schizophrenic Patients .pdf.jpgGenerated Thumbnailimage/jpeg1703https://bonga.unisimon.edu.co/bitstreams/0e503c74-b09e-48e9-8dc9-7d89f9fd07b8/download2bc2614ff9fbae06862fcfbcddd735edMD55PDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg5818https://bonga.unisimon.edu.co/bitstreams/d74fbe2f-8825-4a7e-b08e-70144926d622/download8a6e6c9ad5ebc6e57e806bfde4856b10MD5720.500.12442/3021oai:bonga.unisimon.edu.co:20.500.12442/30212024-08-14 21:53:31.704http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internacionalopen.accesshttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.coPGEgcmVsPSJsaWNlbnNlIiBocmVmPSJodHRwOi8vY3JlYXRpdmVjb21tb25zLm9yZy9saWNlbnNlcy9ieS1uYy80LjAvIj48aW1nIGFsdD0iTGljZW5jaWEgQ3JlYXRpdmUgQ29tbW9ucyIgc3R5bGU9ImJvcmRlci13aWR0aDowIiBzcmM9Imh0dHBzOi8vaS5jcmVhdGl2ZWNvbW1vbnMub3JnL2wvYnktbmMvNC4wLzg4eDMxLnBuZyIgLz48L2E+PGJyLz5Fc3RhIG9icmEgZXN0w6EgYmFqbyB1bmEgPGEgcmVsPSJsaWNlbnNlIiBocmVmPSJodHRwOi8vY3JlYXRpdmVjb21tb25zLm9yZy9saWNlbnNlcy9ieS1uYy80LjAvIj5MaWNlbmNpYSBDcmVhdGl2ZSBDb21tb25zIEF0cmlidWNpw7NuLU5vQ29tZXJjaWFsIDQuMCBJbnRlcm5hY2lvbmFsPC9hPi4=

Second Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a))

Publicaciones similares